Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10324914 | 1.00 | HMGCR (0.40) | HMGCRNLRP3 | |
| SCHEMBL12897959 | 0.85 | NLRP3 (0.41) | HMGCRNLRP3 | |
| SCHEMBL12897961 | 0.85 | NLRP3 (0.41) | HMGCRNLRP3 | |
| SCHEMBL20617446 | 0.84 | NLRP3 (0.44) | NLRP3 | |
| SCHEMBL9272620 | 0.83 | NLRP3 (0.36) | NLRP3 | |
| SCHEMBL9269795 | 0.83 | NLRP3 (0.36) | NLRP3 | |
| SCHEMBL9348220 | 0.83 | NLRP3 (0.36) | NLRP3 | |
| SCHEMBL13768714 | 0.81 | HMGCR (0.43) | HMGCR | |
| SCHEMBL10041024 | 0.81 | HMGCR (0.43) | HMGCR | |
| SCHEMBL13260909 | 0.78 | HMGCR (0.41) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655650-B1 | ENZYMATIC SYNTHESIS OF ACTIVE PHARMACEUTICAL INGREDIENT AND INTERMEDIATES THEREOF | LEK PHARMACEUTICALS (SI) | 2017-12-20 | — | — | EP | disclosed |
| US-20130337485-A1 | ENZYMATIC SYNTHESIS OF ACTIVE PHARMACEUTICAL INGREDIENT AND INTERMEDIATES THEREOF | LEK PHARMACEUTICALS D.D (SI) | 2013-12-19 | — | — | US | disclosed |
| EP-2655650-A2 | ENZYMATIC SYNTHESIS OF ACTIVE PHARMACEUTICAL INGREDIENT AND INTERMEDIATES THEREOF | LEK Pharmaceuticals d.d. (SI) | 2013-10-30 | — | — | EP | disclosed |
| US-8404870-B2 | ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof | LEK PHARMACEUTICALS D.D. (SI) | 2013-03-26 | — | — | US | disclosed |
| US-8404870-B2 | ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof | LEK PHARMACEUTICALS D.D. (SI) | 2013-03-26 | — | — | US | disclosed |
| WO-2012095244-A2 | ENZYMATIC SYNTHESIS OF ACTIVE PHARMACEUTICAL INGREDIENT AND INTERMEDIATES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-07-19 | — | — | WO | disclosed |
| EP-2465936-A1 | Enzymatic synthesis of statins and intermediates thereof | LEK Pharmaceuticals d.d. (SI) | 2012-06-20 | — | — | EP | disclosed |
| US-20110046375-A1 | ((2S,4R)-4,6-DIHYDROXYTETRAHYDRO-2H-PYRAN-2-YL)METHYL CARBOXYLATE AND PROCESS FOR THE PRODUCTION THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2011-02-24 | — | — | US | disclosed |
| US-20110046375-A1 | ((2S,4R)-4,6-DIHYDROXYTETRAHYDRO-2H-PYRAN-2-YL)METHYL CARBOXYLATE AND PROCESS FOR THE PRODUCTION THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046375-A1 | ((2S,4R)-4,6-DIHYDROXYTETRAHYDRO-2H-PYRAN-2-YL)METHYL CARBOXYLATE AND PROCESS FOR THE PRODUCTION THEREOF | HMGCR, CYP4A11, CYP4B1 | HMGCR 1/4885NLRP3 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.